Insulin-like growth factor and lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 7, 2006, Pages 607-610

  Velcheti, Vamsidhar ^a   Govindan, Ramaswamy ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

Insulin like growth factor; Non small cell lung cancer

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CP 751871; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETOPOSIDE; GROWTH HORMONE ANTIBODY; H7C10; HORMONE RECEPTOR BLOCKING AGENT; IMMUNOGLOBULIN G1 ANTIBODY; INSULIN LIKE GROWTH FACTOR 1 ANTIBODY; M 610; MONOCLONAL ANTIBODY; NAVELBINE; PROTEIN INHIBITOR; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; UNITED STATES; DRUG ANTAGONISM; LUNG TUMOR; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

HUMANS; LUNG NEOPLASMS; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 34247897234     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/s1556-0864(15)30370-1     Document Type: Review

References (48)

1. Antoniades HN, Beigelman PM, Pennell RB, Thorn GW, Oncley JL. Insulin-like activity of human plasma constituents. III. Elution of insulin-like activity from cationic exchange resins. Metabolism 1958;7:266-268.
2. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
3. Rotwein P. Structure, evolution, expression and regulation of insulin-like growth factors I and II. Growth Factors 1991;5:3-18.
4. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998;140:19-24.
5. Wolk A. The growth hormone and insulin-like growth factor I axis, and cancer. Lancet 2004;363:1336-1337.
6. Fowlkes JL, Serra DM, Bunn RC, Thrailkill KM, Enghild JJ, Nagase H. Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes. Endocrinology 2004;145:620-626.
7. Miyamoto S, Yano K, Sugimoto S, et al. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 2004;64:665-671.
8. Nakamura M, Miyamoto S, Maeda H, et al. Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun 2006;333:1011-1016.
9. Mochizuki S, Shimoda M, Shiomi T, Fujii Y, Okada Y. ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun 2004;315:79-84.
10. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53-and IGF-independent mechanism. J Biol Chem 1997;272:12181-12188.
11. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 2006;16:421-439.
12. Fowden AL. The insulin-like growth factors and feto-placental growth. Placenta 2003;24:803-812.
13. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518.
14. Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends Biochem Sci 2002;27:352-360.
15. Linnerth NM, Baldwin M, Campbell C, Brown M, McGowan H, Moorehead RA. IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells. Oncogene 2006;24:7310-7319.
16. Moorehead RA, Sanchez OH, Baldwin RM, Khokha R. Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene 2003;22:853-857.
17. Scott CD, Firth SM. The role of the M6P/IGF-II receptor in cancer: tumor suppression or garbage disposal? Horm Metab Res 2004;36:261-271.
18. Minuto F, Del Monte P, Barreca A, Alama A, Cariola G, Giordano G. Evidence for autocrine mitogenic stimulation by somatomedin-C/insulin-like growth factor I on an established human lung cancer cell line. Cancer Res 1988;48:3716-3719.
19. Minuto F, Del Monte P, Barreca A, et al. Evidence for an increased somatomedin-C/insulin-like growth factor I content in primary human lung tumors. Cancer Res 1986;46:985-988.
20. Izycki T, Chyczewska E, Naumnik W, Talalaj J, Panek B, Ossolinska M. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy. Exp Oncol 2004;26:316-319.
21. Reeve JG, Morgan J, Schwander J, Bleehen NM. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 1993;53:4680-4685.
22. Kohda M, Hoshiya H, Katoh M, et al. Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol Carcinogen 2001;31:184-191.
23. Kong FM, Anscher MS, Washington MK, Killian JK, Jirtle RL. M6P/ IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 2000;19:1572-1578.
24. Tsujiuchi T, Sasaki Y, Tsutsumi M, Konishi Y. Alterations of the M6p/Igf2 receptor gene in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl) amine in rats. Mol Carcinogen 2003;36:32-37.
25. Gemma A, Hosoya Y, Uematsu K, et al. Mutation analysis of the gene encoding the human mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) in human cell lines resistant to growth inhibition by transforming growth factor beta(1) (TGF-beta(1)). Lung Cancer 2000;30:91-98.
26. Kaiser U, Schardt C, Brandscheidt D, Wollmer E, Havemann K. Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol 1993;119:665-668.
27. Rotsch M, Maasberg M, Erbil C, Jaques G, Worsch U, Havemann K. Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines. J Cancer Res Clin Oncol 1992;118:502-508.
28. Schardt C, Rotsch M, Erbil C, Goke R, Richter G, Havemann K. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp Cell Res 1993;204:22-29.
29. Long L, Rubin R, Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 1998;238:116-121.
30. Chang YS, Kong G, Sun S, et al. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 2002;8:3796-3802.
31. Chang YS, Wang L, Liu D, et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002;8:3669-3675.
32. London SJ, Yuan JM, Travlos GS, et al. Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 2002;94:749-754.
33. Reeve JG, Brinkman A, Hughes S, Mitchell J, Schwander J, Bleehen NM. Expression of insulinlike growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines. J Natl Cancer Inst 1992;84:628-634.
34. Rudd MF, Webb EL, Matakidou A, et al. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res 2006;16:693-701.
35. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-156.
36. Taylor JE, Bogden AE, Moreau JP, Coy DH. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun 1988;153:81-86.
37. Zia F, Jacobs S, Kull F, Cuttitta F, Mulshine JL, Moody TW. Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J Cell Biochem Suppl 1996;24:269-275.
38. Lee CT, Wu S, Gabrilovich D, et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 1996;56:3038-3041.
39. Jiang Y, Rom WN, Yie TA, Chi CX, Tchou-Wong KM. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene 1999;18:6071-6077.
40. Goetsch L, Gonzalez A, Leger O, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2006;113:316-328.
41. Warshamana-Greene GS, Litz J, Buchdunger E, Garcia-Echeverria C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2006;11:1563-1571.
42. Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 2004;90:1825-1829.
43. Cosaceanu D, Carapancea M, Castro J, Ekedahl J, Kanter L, Lewensohn R, Dricu A. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett 2006;222:173-181.
44. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006;5:114-120.
45. Lee H-Y, Moon H, Chun K-H, et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst 2004;96:1536-1548.
46. Hochscheid R, Jaques G, Wegmann B. Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer. J Endocrinol 2000;166:553-563.
47. Qingnan Y, Banerjee K, Paterson J, Alami N, Shiry L, Leyland-Jones B. Insulin-like growth factor binding protein-3: single-agent and synergistic effects with chemotherapeutic drugs on solid tumor models [Abstract 1437]. American Association for Cancer Research, 2003 July 11-14.
48. Jerome L, Shiry L, Leyland-Jones B. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003;10:561-578.